First Trust Amex Biotech Index Fund (FBT)

“A biotech index concentrated in the innovators before they become household names — capturing the sector’s risk and potential all at once.”

First Trust Amex Biotech Index Fund gives investors exposure to U.S.-listed biotech and biopharmaceutical companies by tracking the NYSE AMEX Biotech Index, a sector-focused benchmark that tilts toward smaller and mid-cap firms. For investors who believe that innovation in drug discovery, genetic engineering, and molecular medicine will drive long-term returns, and who are willing to accept the volatility that comes with early-stage healthcare innovation, FBT provides a focused, tradeable way to bet on that thesis.

The biotech sector and why it matters

Biotech companies are in the business of discovering, developing, and commercializing new drugs, biologics, and therapies. Unlike large pharmaceutical companies that may have dozens of marketed drugs and steady cash flows from existing products, most biotech firms are organized around a handful of candidates in various stages of clinical trials. A single success — a drug approved by the FDA that reaches the market — can transform a firm’s value; a failure or a delayed trial can be catastrophic. This binary nature makes biotech inherently riskier than many sectors, but it also explains why investors are willing to hold it: the potential returns from a transformative therapy can be extraordinary.

The biotech index that FBT tracks is deliberately tilted toward the innovators and the small to mid-cap players who are doing much of the cutting-edge work. Large pharmaceutical companies trade on different indices because their business models are different: they own factories, have marketing armies, and are more mature. The biotech index concentrates on the thinner end of the market — firms that have gone public to fund their research but may not yet be profitable, and whose primary asset is intellectual property and a pipeline of early-stage therapies.

Structure and holdings

The NYSE AMEX Biotech Index is a modified market-cap-weighted basket of U.S.-listed biotech and biopharmaceutical companies. FBT holds a diversified set of them, typically 50 to 100 companies, which provides some protection against the binary risk of any single company but still leaves the portfolio highly exposed to sector-wide trends in drug approvals, regulatory decisions, and financing conditions.

Holdings range from relatively well-known names — established biotech firms with approved products on the market — to smaller companies in preclinical or early clinical stages of development. This tilt toward smaller companies makes FBT more growth-oriented and more volatile than, say, the larger pharmaceutical index. The fund rebalances to track the index on a regular basis, so the weights shift as company market values change.

Sector dynamics and what moves the index

Biotech stock performance is driven by a handful of macro and micro forces. On the macro side, interest rates matter enormously: when the federal funds rate is high, investors demand higher returns and are less willing to pay for speculative future cash flows, so biotech stocks typically struggle. Conversely, when rates are low, growth investors are more tolerant of unprofitable companies with long timelines, and biotech can rally sharply.

On the micro side, individual regulatory decisions — FDA approvals or rejections of key drugs, changes in reimbursement policy, or surprise trial results from major companies — can move the sector by points in a day. Because the index includes many companies with upcoming catalysts (trial readouts, approvals), FBT carries significant event risk: a cluster of disappointments can drive the entire index lower, while a wave of approvals or positive data can lift it.

The biotech sector also runs counter-cyclical to the broader economy sometimes: when growth stocks struggle, investors hunt for upside, and biotech can attract money. Other times, biotech is just another volatile equity sector and moves with risk appetite overall.

Costs and trading

First Trust’s expense ratio for FBT is moderate — higher than a broad market ETF because the index is actively maintained and is narrower, but lower than an actively managed biotech fund would charge. The fund trades on the NASDAQ with reasonable liquidity, though trading volume is lower than a mega-cap stock index ETF; bid-ask spreads can widen during market stress.

The risks of biotech concentration

Holding a concentrated basket of biotech stocks means accepting several layers of risk. Clinical trial risk is the most obvious: the majority of drugs that enter human trials never make it to approval, and even small changes in trial design or regulatory interpretation can shift outcomes. Financing risk also matters: smaller biotech companies are cash burners by design and may need to raise money at unfavorable terms if markets turn. Patent risk — the possibility that a competitor develops a better therapy or a patent challenge invalidates a company’s protection — is always present. And liquidity risk exists for the smallest holdings in the fund.

The sector-concentration risk is perhaps the subtlest: FBT is not a diversified portfolio of all equities; it is a bet on one slice of the market, and it will underperform for extended periods when investors move away from biotech toward more defensive assets.

Who it is for and how to research it

FBT suits investors with a long time horizon who want explicit exposure to biotech innovation and can tolerate significant volatility. It is typically a satellite holding rather than a core position — a 5–15% slice of an equity portfolio for someone with strong conviction about healthcare innovation or a demographic thesis (aging populations driving drug development). It is not appropriate for conservative investors or those with a short time horizon.

To research FBT, read the fund’s prospectus carefully and monitor the composition of the index; check which holdings are the most heavily weighted and what catalysts (trial dates, approvals, patent expirations) are coming for the largest positions. Follow biotech news and FDA decisions to understand sector sentiment. Compare FBT to other biotech indices and sector funds to decide if the NYSE AMEX’s specific mix aligns with your thesis. Remember that biotech is for patient, risk-tolerant capital.